Literature DB >> 10913726

Growth hormone deficiency in children with neurofibromatosis type 1 without suprasellar lesions.

R Vassilopoulou-Sellin1, M J Klein, J K Slopis.   

Abstract

Risk factors for shortness of stature in children with neurofibromatosis type 1 (NF-1) include suprasellar lesions, which can lead to growth hormone deficiency (GHD), skeletal deformities, nutritional insufficiency, and methylphenidate use. At our Neurofibromatosis Clinic, we have observed short children growing poorly without these risk factors. This study investigated whether GHD occurs in children with NF-1 in the absence of suprasellar lesions. Of 251 children with NF-1, 112 were at or below the 25th percentile for height (68 were at or below the 10th). Of these, 51 children, 5-16 years of age were short, growing poorly, and without medical or radiologic findings to explain the poor growth. In 19 of 51, we evaluated GH secretion; 15 of 19 had GHD (peak GH level less than 5 ng/mL in most cases). These findings suggest that GHD may be relatively common in short children with NF-1 without suprasellar abnormalities, suggesting an association with NF-1 independent of organic, pituitary damage. Larger cohorts of NF-1 children should be evaluated to clarify whether NF-1 represents a novel etiology of GHD. Also, a careful assessment of GH secretion in children with NF-1 who are growing poorly in the absence of another clinical explanation is warranted.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10913726     DOI: 10.1016/s0887-8994(00)00123-5

Source DB:  PubMed          Journal:  Pediatr Neurol        ISSN: 0887-8994            Impact factor:   3.372


  13 in total

Review 1.  Risk of Neoplasia in Pediatric Patients Receiving Growth Hormone Therapy--A Report From the Pediatric Endocrine Society Drug and Therapeutics Committee.

Authors:  Sripriya Raman; Adda Grimberg; Steven G Waguespack; Bradley S Miller; Charles A Sklar; Lillian R Meacham; Briana C Patterson
Journal:  J Clin Endocrinol Metab       Date:  2015-04-03       Impact factor: 5.958

2.  Height assessments in children with neurofibromatosis type 1.

Authors:  Elizabeth A Soucy; Dorothy van Oppen; Nicole L Nejedly; Feng Gao; David H Gutmann; Abby S Hollander
Journal:  J Child Neurol       Date:  2012-06-29       Impact factor: 1.987

3.  Optic pathway glioma and endocrine disorders in patients with and without NF1.

Authors:  Merav Gil Margolis; Michal Yackobovitz-Gavan; Helen Toledano; Ariel Tenenbaum; Roni Cohen; Moshe Phillip; Shlomit Shalitin
Journal:  Pediatr Res       Date:  2022-05-10       Impact factor: 3.756

4.  Neurofibromin regulates somatic growth through the hypothalamic-pituitary axis.

Authors:  Balazs Hegedus; Tu-Hsueh Yeh; Da Yong Lee; Ryan J Emnett; Jia Li; David H Gutmann
Journal:  Hum Mol Genet       Date:  2008-07-09       Impact factor: 6.150

5.  Partial empty sella syndrome, GH deficiency and transient central adrenal insufficiency in a patient with NF1.

Authors:  Eleni Magdalini Kyritsi; Maria Hasiotou; Christina Kanaka-Gantenbein
Journal:  Endocrine       Date:  2020-06-09       Impact factor: 3.633

6.  Neurofibromatosis 1-associated panhypopituitarism presenting as hypoglycaemic seizures and stroke-like symptoms.

Authors:  Waqar Waheed; Muriel H Nathan; Gilman B Allen; Neil M Borden; M Ali Babi; Rup Tandan
Journal:  BMJ Case Rep       Date:  2015-11-03

7.  Growth Hormone Deficiency in a Child with Neurofibromatosis-Noonan Syndrome.

Authors:  Doğuş Vurallı; Nazlı Gönç; Dominique Vidaud; Alev Özön; Ayfer Alikaşifoğlu; Nurgün Kandemir
Journal:  J Clin Res Pediatr Endocrinol       Date:  2015-12-18

Review 8.  Emerging genotype-phenotype relationships in patients with large NF1 deletions.

Authors:  Hildegard Kehrer-Sawatzki; Victor-Felix Mautner; David N Cooper
Journal:  Hum Genet       Date:  2017-02-17       Impact factor: 4.132

9.  Neurofibromatosis type 1 of the child increases birth weight.

Authors:  Jussi Leppävirta; Roope A Kallionpää; Elina Uusitalo; Tero Vahlberg; Minna Pöyhönen; Juha Peltonen; Sirkku Peltonen
Journal:  Am J Med Genet A       Date:  2019-04-24       Impact factor: 2.802

Review 10.  Cutaneous neurofibromas in the genomics era: current understanding and open questions.

Authors:  Robert J Allaway; Sara J C Gosline; Salvatore La Rosa; Pamela Knight; Annette Bakker; Justin Guinney; Lu Q Le
Journal:  Br J Cancer       Date:  2018-04-26       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.